MicroOptx Medical

MicroOptx Medical

• 1.
  The technology toconquer glaucoma Chris Pulling CEO [email protected]
• 2.
  BG Implant Overview Novel nanotechnology implant that shunts aqueous directly to the tear film without risk of internal infection  >$1MM already invested by principals; >$3.4MM total  Just closing $2.2MM series B  Funding through 10 patient US feasibility trial  Successful prototype development with foundational bench and animal data  Proven, expert and hands-on leadership team  Clear and achievable regulatory AND reimbursement path
• 3.
  Glaucoma  Common :105 million WW, doubling in 20 years  Devastating : second leading cause of blindness in the world (cataracts)  Leading cause of irreversible blindness  polls show shorter life preferred over blindness  Unmet Need : no treatment universally accepted as safe and effective; WHO has dropped glaucoma screening
• 4.
  The Brown GlaucomaImplant  Shunts directly to the tear film  No bleb  Not shunting to enclosed space within eye; scarring/plugging is not a failure mode  No episcleral venous pressure component => resorption, nocturnal supine IOP increase  Has a filter providing precise flow control (P=RxF)  Filter is the only source of resistance to AH outflow  Engineered to achieve 8-12mmHg IOP  Surface biocompatibility good; hydration shell in inner lumen resists attachments of proteins, cells, and bacteria  Bulk biocompatibility good. Rigidity match with sclera + surface biointegration = no micromotion  Three issued patents; two provisionals filed
• 5.
  Dime BG Implant Current Technology Dime
• 6.
  Collagen Type 1 CollagenType 1 Structural Polymer Polyethylene Glycol (low MW) Polyethylene Glycol (high MW) Polyethylene Glycol (low MW) Polyethylene Glycol (high MW) Structural Polymer AH Outflow Filter Nanofabrication / micromachining P=FxR (PEG)
• 7.
  Self- priming Lumen’s PEG surface: Veryhydrophilic
• 8.
  (bacterial broth)
• 9.
  Pressure in 2-WeekFlow Test 0 48 96 144 192 240 288 336 0 10 20 30 40 50 PressureDrop(mmHg) Time (hour) Flow rate: 2.5 ml/min (physiological)
• 10.
  Complete Bacterial Exclusionafter 2-weeks Outlet Inlet Flow No bacteria were found inside the device BacterialBroth
• 11.
  Initial Animal SafetyTesting  Easily implantable  Tolerated well  Securely scarred into place  No infection, with no PMNs or bacteria seen within or around the device  Constant AH bathing of cornea not irritant  OSD, dry eye
• 12.
  MicroOptx Summary  ShuntsAH directly to the tear film: no bleb; no EVP component to raise nocturnal IOP  Hits Threshold IOP, and no hypotony  Inner lumen PEG: resists bacterial, protein, and cell adherence  Biointegrates with sclera, so no tunnel infection risk  In human trials in 9-12 months
• 13.
  Ending the worldsleading cause of blindness